Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 2/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933699 | 0.91 | OPRK1 (0.41) | OPRK1OXTRAVPR1AP2RY12AVPR2 | |
| SCHEMBL25333905 | 0.87 | NR1H2 (0.39) | OPRK1OXTRAVPR1AP2RY12AVPR2 | |
| SCHEMBL31121722 | 0.84 | OPRK1 (0.44) | OPRK1P2RY12NR1H2NR1H3ABL1 | |
| SCHEMBL19689526 | 0.84 | OPRK1 (0.44) | OPRK1P2RY12NR1H2NR1H3ABL1 | |
| SCHEMBL24214266 | 0.81 | OPRK1 (0.53) | OPRK1P2RY12ABL1 | |
| SCHEMBL25333591 | 0.81 | MAPK1 (0.35) | OPRK1NR1H2NR1H3POLBMAPT | |
| SCHEMBL24215693 | 0.79 | OPRK1 (0.45) | OPRK1P2RY12MAPTHDAC6 | |
| SCHEMBL30516578 | 0.79 | OPRK1 (0.45) | OPRK1P2RY12MAPTHDAC6 | |
| SCHEMBL4131161 | 0.78 | OPRK1 (0.51) | OPRK1P2RY12MAPTHDAC6 | |
| SCHEMBL19689497 | 0.77 | OPRK1 (0.42) | OPRK1P2RY12NR1H2NR1H3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | OPRK1 1823/4885VNN1 4826/4885OXTR 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.